1372 / 1851
PCR
Capecitabine/oxaliplatin pCR = 21% (10/48)
capecitabine/irinotecan pCR = 10% (5/48)
so the irinotecan arm was rejected
But long-term follow-up showed
•
Numerically superior survival (4-year OS: 85%
v 75%; P > .05)
•
The 4-year DFS 68% versus 62%.
Wong SJ et al. IJROBP 2015; 91(1):116-123